Sinocelltech Group Ltd
Company Profile
Business description
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Contact
Kechuang Seventh Street
Beijing Economic and Technological Development Zone
Room 307, Building 5, Courtyard 31
Beijing100176
CHNT: +86 1058628288
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2,277
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,069.00 | 14.40 | -0.16% |
| CAC 40 | 8,103.58 | 0.27 | -0.00% |
| DAX 40 | 24,340.06 | 56.09 | 0.23% |
| Dow JONES (US) | 48,442.41 | 79.73 | 0.16% |
| FTSE 100 | 9,870.68 | 18.54 | -0.19% |
| HKSE | 25,818.93 | 44.79 | 0.17% |
| NASDAQ | 23,561.84 | 133.02 | 0.57% |
| Nikkei 225 | 50,344.10 | 68.77 | -0.14% |
| NZX 50 Index | 13,529.06 | 11.33 | 0.08% |
| S&P 500 | 6,909.79 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,762.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,940.95 | 20.97 | 0.53% |